INS and diabetes mellitus: As insulin-sensitizing agents, TZDs have been used widely for diabetes patients and have been demonstrated to have the effects of both anti-inflammation and anti-proliferation mediated by binding to PPAR-γ30–33 and eventually attenuate the development of intimal hyperplasia after PCI to reduce the rates of ISR and TLR.